Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib). These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of therapy. Data from the study were featured in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract #797).“There are currently no comparative clinical trials in first-line CLL among the BTKi class, highlighting the critical need to leverage real-world experience to support optimized treatment selection,” said Ryan Jacobs†, M.D., Clinical Director, Division of Lymphoma Therapy & Research, Department of Hematologic Oncology, Atrium Health Levine Cancer Institute and principal study investigator. “These results demonstrate the possible impact of using ibrutinib versus acalabrutinib in the front-line setting and provide healthcare professionals with additional data showing differences in time to next treatment.”The study used Acentrus‡, de-identified academic electronic medical records (EMR) to i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
More News: Academia | Acute Leukemia | Allergy & Immunology | Anemia | Arrhythmia | Atrial Fibrillation | Bilirubin | Biotechnology | Bleeding | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiac Arrhythmia | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Child Development | Children | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Pain | Clinical Trials | Databases & Libraries | Diabetes | Diabetes Mellitus | Electronic Medical Records (EMR) | Endocrinology | Environmental Health | Food and Drug Administration (FDA) | Gastroenterology | Genetics | Grapefruit | Headache | Health Management | Heart | Hematology | Hodgkin's Disease | Hormones | Hypertension | Infectious Diseases | Laboratory Medicine | Learning | Legislation | Leukemia | Lymphoma | Macroglobulinemia | Melanoma | Migraine | Neurology | Neuroscience | Neurosurgery | Non-Hodgkin's Lymphoma | Nonmelanoma Skin Cancer | Oral Cancer | Oranges | Pain | Pediatrics | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Pregnancy | Primary CNS Lymphoma | Pulmonary Hypertension | Science | Skin | Skin Cancer | Skin Graft | Study | Thrombocytopenia | Toxicology | Universities & Medical Training | Vaccines | Veterinary Vaccinations | Waldenstrom's Macroglobulinemia | Women